BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference

LAVAL, QC, May 9, 2013 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") today announced that Roberto Bellini, President and Chief Executive Officer, will present at the second annual Bloom Burton & Co. Healthcare Investor Conference. The presentation will take place at 4:00 pm Eastern Time on Wednesday, May 22, 2013. The conference is being held at the Toronto Board of Trade in Toronto, Ontario.

Mr. Bellini will provide a corporate update, including information about the Phase III Confirmatory Study for KIACTA™, BELLUS Health's drug candidate for the treatment of AA amyloidosis.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About BELLUS Health (

BELLUS Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company's lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics (previously Celtic Therapeutics). AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.


For further information:

Adam Peeler
TMX Equicom
416-815-0700 ext. 225 |


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.